Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | TPMT | P51580 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12970676 | 0.89 | KMT2A (0.53) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2164333 | 0.89 | ALDH1A1 (0.64) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2427327 | 0.89 | CA12 (0.70) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15540848 | 0.87 | MAPK1 (0.55) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5900859 | 0.87 | PRSS1 (0.55) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL335681 | 0.86 | MAPK1 (0.77) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29415167 | 0.86 | MAPK1 (0.77) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6512640 | 0.85 | MAPK1 (0.60) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12505536 | 0.84 | FLT3 (0.53) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19988183 | 0.84 | FLT3 (0.53) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3183255-B1 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC (US) | 2023-07-05 | — | — | EP | claimed |
| US-9701685-B2 | Spiropyrrolidines as MDM2 inhibitors | HUDSON BIOPHARMA INC. (US) | 2017-07-11 | — | — | US | claimed |
| EP-3183255-A2 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | Hudson Biopharma Inc. (US) | 2017-06-28 | — | — | EP | claimed |
| WO-2016028391-A9 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC. (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2016028391-A2 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC. (US) | 2016-02-25 | — | — | WO | claimed |
| US-20150322076-A1 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC. | 2015-11-12 | — | — | US | claimed |
| EP-2406250-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2015-08-12 | — | — | EP | claimed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | claimed |
| US-8614221-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2013-12-24 | — | — | US | claimed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | claimed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | claimed |
| US-8217044-B2 | Spiroindolinone pyrrolidines | HOFFMANN-LA ROCHE INC. (US) | 2012-07-10 | — | — | US | claimed |
| WO-2012007409-A1 | N-SUBSTITUTED PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| EP-3183255-B1 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | HUDSON BIOPHARMA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-113387957-B | Spirocyclic indolone-pyrrolidine carbonate compound and composition, preparation method and application thereof | 江苏亚尧生物科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2012007409-A1 | N-SUBSTITUTED PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | MAPK1 3630/4885TSHR 846/4885CYP1A2 730/4885 |
| US-20150322076-A1 | SPIROPYRROLIDINES AS MDM2 INHIBITORS | TP53, RB1, MDM2 | MAPK1 1096/4885TSHR 3641/4885CYP1A2 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.